1. Home
  2. ADPT vs PDM Comparison

ADPT vs PDM Comparison

Compare ADPT & PDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADPT
  • PDM
  • Stock Information
  • Founded
  • ADPT 2009
  • PDM 1997
  • Country
  • ADPT United States
  • PDM United States
  • Employees
  • ADPT N/A
  • PDM N/A
  • Industry
  • ADPT Biotechnology: Biological Products (No Diagnostic Substances)
  • PDM Building operators
  • Sector
  • ADPT Health Care
  • PDM Real Estate
  • Exchange
  • ADPT Nasdaq
  • PDM Nasdaq
  • Market Cap
  • ADPT 929.8M
  • PDM 1.1B
  • IPO Year
  • ADPT 2019
  • PDM N/A
  • Fundamental
  • Price
  • ADPT $6.81
  • PDM $8.81
  • Analyst Decision
  • ADPT Buy
  • PDM Buy
  • Analyst Count
  • ADPT 4
  • PDM 3
  • Target Price
  • ADPT $6.75
  • PDM $10.67
  • AVG Volume (30 Days)
  • ADPT 1.3M
  • PDM 753.6K
  • Earning Date
  • ADPT 02-12-2025
  • PDM 02-13-2025
  • Dividend Yield
  • ADPT N/A
  • PDM 5.67%
  • EPS Growth
  • ADPT N/A
  • PDM N/A
  • EPS
  • ADPT N/A
  • PDM N/A
  • Revenue
  • ADPT $177,282,000.00
  • PDM $572,424,000.00
  • Revenue This Year
  • ADPT $6.48
  • PDM N/A
  • Revenue Next Year
  • ADPT $18.72
  • PDM $0.18
  • P/E Ratio
  • ADPT N/A
  • PDM N/A
  • Revenue Growth
  • ADPT N/A
  • PDM N/A
  • 52 Week Low
  • ADPT $2.28
  • PDM $5.93
  • 52 Week High
  • ADPT $7.46
  • PDM $11.12
  • Technical
  • Relative Strength Index (RSI)
  • ADPT 54.92
  • PDM 46.58
  • Support Level
  • ADPT $5.98
  • PDM $8.45
  • Resistance Level
  • ADPT $7.28
  • PDM $8.93
  • Average True Range (ATR)
  • ADPT 0.54
  • PDM 0.25
  • MACD
  • ADPT -0.00
  • PDM 0.03
  • Stochastic Oscillator
  • ADPT 58.06
  • PDM 55.50

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

About PDM Piedmont Office Realty Trust Inc.

Piedmont Office Realty Trust Inc is a real estate investment trust engaged in the acquisition, development, and management of commercial real estate properties throughout the U.S. The company's real estate portfolio is mainly composed of office properties located in the majority of American metropolitan areas. Piedmont derives majority of its revenue in the form of rental income from tenants in mid- to long-term lease agreements. The vast majority of the company's revenue comes from the leasing of its assets in Washington D.C., New York City, Chicago, Atlanta, Minneapolis, Dallas, and Boston. Piedmont's large customers in terms of rental revenue are U.S. Government entities, business services companies, and financial institutions.

Share on Social Networks: